NCT06465199

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-05-13Est. Completion: 2033-05

Enrollment target: 289 participants

Locations

University of Alabama/Children's of Alabama, Birmingham, Alabama, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Connecticut Children's Hospital, Hartford, Connecticut, United States
Nicklaus Children's Hospital, Miami, Florida, United States
Arnold Palmer Hospital for Children, Orlando, Florida, United States
St. Joseph's Children's Hospital, Tampa, Florida, United States
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States
Children's Medical Center, Dallas, Texas, United States

Contact

BCC EnrollBCCEnroll@pennstatehealth.psu.edu

Other microbiome trials you might be interested in

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid TumorsRecruiting

Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid TumorRefractory Solid TumorsSolid Tumor

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors or…

Bethesda, United StatesEst. completion May 31, 2028

View Trial →

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPhase 3Recruiting

Clear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph NodesMetastatic Malignant Neoplasm in the Soft Tissue

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.